Roiver Score™ for
SABSSAB Biotherapeutics, Inc. Common Stock
Biological Products, (No Diagnostic Substances)
Based on fundamentals through 12/31/2025.
As of December 31, 2025, SAB Biotherapeutics, Inc. Common Stock (SABS) scores 12/100 (Weak) on the Roiver Score — a transparent quality composite. Its strongest area is profitability; its weakest is stability. The score measures business quality, not timing — it's a signal, not a recommendation.
No black box
Roiver Score is a transparent 0–100 quality composite. Five components, each 0–20: profitability, capital structure, cash quality, valuation, and stability. Inspired by Piotroski's F-Score, Altman's Z-Score, and the Buffett/Munger framework on quality compounders at fair prices. Read the full methodology →
Frequently asked about SABS
What is SABS's Roiver Score?
SAB Biotherapeutics, Inc. Common Stock scores 12 out of 100 (Weak) as of December 31, 2025, based on fundamentals.
How is the Roiver Score for SABS calculated?
It sums five 0–20 components — profitability, capital structure, cash quality, valuation, and stability — into a transparent 0–100 composite. The full methodology is published.
Is SABS a good quality stock?
On quality, SABS rates "Weak" (12/100). Its strongest driver is profitability and its weakest is stability. Quality is one input to a decision, not a buy/sell call.
Embed on your site
Drop this iframe into a Substack, blog post, or notion page. Updates automatically as fundamentals change.
<iframe src="https://roiver.com/embed/score/SABS" width="640" height="280" frameborder="0" style="border:0;border-radius:16px;overflow:hidden" loading="lazy"></iframe>
Get SABS's Score in your inbox
A free weekly digest of quality scores and what changed. No account needed.
Educational use only. Roiver Score is a quality signal, not a recommendation.